Timothy Y Y Lai1, Raymond L M Wong2, Wai-Man Chan3. 1. Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong 2010 Retina & Macula Centre, Kowloon, Hong Kong. 2. Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong. 3. Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong and Department of Ophthalmology, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong.
Abstract
PURPOSE: To evaluate whether half-dose verteporfin photodynamic therapy (PDT) is better than natural history for the treatment of central serous chorioretinopathy (CSC). METHODS: Retrospective review of consecutive CSC patients treated with half-dose verteporfin PDT or untreated with observation and a minimum follow-up of 36 months. The main outcome measures included mean change in visual acuity and CSC recurrence. Survival analysis was performed to compare the CSC recurrence rates between the two groups. RESULTS: A total of 192 eyes of 192 patients were included; 75 eyes were treated with half-dose verteporfin PDT and 117 were untreated. The mean follow-up duration was 74.1 months. At the last follow-up, the mean logMAR visual acuity was significantly better in the half-dose verteporfin PDT group compared with the untreated control group (P=.005). The mean visual improvement of the half-dose verteporfin PDT group at the last follow-up was 1.8 lines, compared with 0.0 line in the untreated control group (P<.001). Recurrence of CSC developed in 15 eyes (20%) in the half-dose verteporfin PDT group compared with 63 eyes (53.8%) in the untreated control group (P<.001). Survival analysis demonstrated that eyes treated with half-dose verteporfin PDT were significantly less likely to develop CSC recurrence compared with untreated controls (P<.001). Regression analysis showed that half-dose verteporfin PDT was the only significant factor in reducing the risk of CSC recurrence. CONCLUSIONS: Half-dose verteporfin PDT for the treatment of CSC resulted in significantly better visual acuity outcomes and lower recurrence rate in the long term compared with untreated controls.
PURPOSE: To evaluate whether half-dose verteporfin photodynamic therapy (PDT) is better than natural history for the treatment of central serous chorioretinopathy (CSC). METHODS: Retrospective review of consecutive CSC patients treated with half-dose verteporfin PDT or untreated with observation and a minimum follow-up of 36 months. The main outcome measures included mean change in visual acuity and CSC recurrence. Survival analysis was performed to compare the CSC recurrence rates between the two groups. RESULTS: A total of 192 eyes of 192 patients were included; 75 eyes were treated with half-dose verteporfin PDT and 117 were untreated. The mean follow-up duration was 74.1 months. At the last follow-up, the mean logMAR visual acuity was significantly better in the half-dose verteporfin PDT group compared with the untreated control group (P=.005). The mean visual improvement of the half-dose verteporfin PDT group at the last follow-up was 1.8 lines, compared with 0.0 line in the untreated control group (P<.001). Recurrence of CSC developed in 15 eyes (20%) in the half-dose verteporfin PDT group compared with 63 eyes (53.8%) in the untreated control group (P<.001). Survival analysis demonstrated that eyes treated with half-dose verteporfin PDT were significantly less likely to develop CSC recurrence compared with untreated controls (P<.001). Regression analysis showed that half-dose verteporfin PDT was the only significant factor in reducing the risk of CSC recurrence. CONCLUSIONS: Half-dose verteporfin PDT for the treatment of CSC resulted in significantly better visual acuity outcomes and lower recurrence rate in the long term compared with untreated controls.
Authors: Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-02-07 Impact factor: 3.117
Authors: Thomas J van Rijssen; Elon H C van Dijk; Greet Dijkman; Camiel J F Boon Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-05-07 Impact factor: 3.117
Authors: Ana Rita Fernandes; Aleksandra Zielińska; Elena Sanchez-Lopez; Tiago Dos Santos; Maria Luisa Garcia; Amelia M Silva; Jacek Karczewski; Eliana B Souto Journal: Int J Mol Sci Date: 2022-02-26 Impact factor: 5.923
Authors: Chui Ming Gemmy Cheung; Won Ki Lee; Hideki Koizumi; Kunal Dansingani; Timothy Y Y Lai; K Bailey Freund Journal: Eye (Lond) Date: 2018-07-11 Impact factor: 3.775
Authors: Thomas J van Rijssen; Elon H C van Dijk; Paula Scholz; Myrte B Breukink; Greet Dijkman; Petrus J H Peters; Roula Tsonaka; Jan E E Keunen; Robert E MacLaren; Carel B Hoyng; Susan M Downes; Sascha Fauser; Camiel J F Boon Journal: Acta Ophthalmol Date: 2021-02-10 Impact factor: 3.761